We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

B. Riley views the selloff in shares of Viking Therapeutics (VKTX) following VK2735 oral weight loss data as overdone. The pullback indicates the ...

Viking Therapeutics (VKTX) stock plunges and short sellers betting against the company gain $521M amid the selloff. Read more here.

Why did Viking Therapeutics stock drop after its obesity drug trial update? Viking Therapeutics shares slumped sharply this week after the company’s latest obesity drug trial update failed to match ...

Viking Therapeutics Inc (NASDAQ: VKTX) reported new clinical data for its oral obesity drug – sending shares sharply lower as ...

Viking Therapeutics (VKTX) stock dove on Tuesday following the release of data from a Phase 2 clinical trial of VK2735. This is the pharmaceutical company’s dual agonist of the glucagon-like peptide 1 ...

Live Updates Live Coverage Has Ended Tuesday Wrap-up 4:12 pm The Vanguard S&P 500 ETF closed at 588.15 Tuesday, down 0.5%.

Rates of adverse events (AEs) gave pause to some on Wall Street, and shares of Viking Therapeutics Inc. (NASDAQ:VKTX) fell 42%, or $17.73, to close Aug. 19 at $24.36 after the firm reported 13-week ...